Skip to main content

OncoNano Medicine Announces Martin Driscoll as Chief Executive Officer
Mr. Driscoll’s deep experience in the biopharmaceutical industry particularly the immuneoncology field makes him ideally suited to assume the leadership of OncoNano Medicine

SOUTHLAKE, TX – February 1, 2021 – OncoNano Medicine, Inc. today announced the
appointment of Martin Driscoll as Chief Executive Officer and a member of the company’s Board
of Directors. An accomplished industry veteran with multiple decades of biopharmaceutical
development and commercialization experience, Mr. Driscoll most recently served as President
and Chief Executive Officer of Spring Bank Pharmaceuticals. Mr. Driscoll succeeds co-founder and
CEO Ravi Srinivasan, Ph.D., who has stepped down in a planned transition to pursue other
“We are thrilled to welcome Marty to our team. Marty’s extensive experience and proven track
record at the helm of several successful biopharmaceutical development companies will
undoubtedly provide OncoNano with the leadership to advance our business and translate our
novel discoveries into important new interventions and treatments for cancer patients,” said Al
Guillem, Ph.D., Chairman of OncoNano. “Marty joins OncoNano at an important time as we
progress our lead program into the pivotal trial stage and advance our first oncology therapeutic,
ONM-501, towards the first human studies for this novel immuno-modulator.” Dr. Guillem
continued, “On behalf of the OncoNano board of directors, I want to thank Ravi for his many
contributions to the growth of our company and wish him great success in his future endeavors.”
“I’m joining OncoNano at an exciting point in the evolution of the company and I look forward to
building on the strong foundation established by Ravi and the OncoNano team as we advance
the clinical development of our impressive portfolio of differentiated programs,” said Mr.
Driscoll. “I was attracted to this opportunity to lead OncoNano by the exciting potential for the
company’s innovative core technology that exploits the universal pH biomarker of solid tumors
to enhance real-time surgical imaging and enable more efficient and effective delivery of cancer
Mr. Driscoll brings a proven record in leading privately-held and publicly-traded
biopharmaceutical development and commercial-stage companies. He has been involved with or
led the commercialization of several important therapies, the direct negotiation of numerous
licensing and M&A transactions, multiple private and public capital fundraising efforts and the
successful submission of major global product regulatory filings. Mr. Driscoll has also served as a
director on the boards of eight biopharmaceutical and diagnostic companies during his career.
About OncoNano Medicine
OncoNano Medicine is developing a new class of products that exploit pH as a biomarker to
diagnose and treat cancer with high specificity. Our product candidates are designed to help
patients across the continuum of cancer care and include solid tumor therapeutics, agents for
real-time image-guided surgery and a platform of product candidates that activate and guide
the body’s immune system to target cancer. Learn more at
Lauren Arnold